戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 l open probability, an event associated with chemotherapy-induced peripheral neuropathy.
2 independent predictors of the development of chemotherapy-induced peripheral neuropathy.
3 lity-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy.
4 re no known effective treatments for painful chemotherapy-induced peripheral neuropathy.
5 tment protocols has the potential to prevent chemotherapy-induced peripheral neuropathy.
6 cularly bortezomib, have significant risk of chemotherapy-induced peripheral neuropathy.
7 ead of VPT measurements in future studies of chemotherapy-induced peripheral neuropathy.
8 s shown to protect axons in animal models of chemotherapy-induced peripheral neuropathy.
9 se effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy.
10  improved the tactile response in a model of chemotherapy-induced peripheral neuropathy.
11 bition has analgesic properties in models of chemotherapy-induced peripheral neuropathy.
12  mechanical and cold allodynia in a model of chemotherapy-induced peripheral neuropathy.
13 eral sclerosis, and neuronal injury, such as chemotherapy-induced peripheral neuropathy.
14 DJ-1 also plays a role in the progression of chemotherapy-induced peripheral neuropathies.
15                Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 scores wer
16 ment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 tool.
17 fe Questionnaire (QLQ) C30 and the EORTC QLQ Chemotherapy-Induced Peripheral Neuropathy 20.
18 Research and Treatment of Cancer (EORTC) QLQ-chemotherapy-induced peripheral neuropathy-20 (CIPN20) i
19 function and this effect is known to mediate chemotherapy-induced peripheral neuropathy and cognitive
20 urotoxicity of cisplatin in rodent models of chemotherapy-induced peripheral neuropathy and explored
21 peutic strategy for the treatment of cancer, chemotherapy-induced peripheral neuropathy, and neurodeg
22          Data on prevention and treatment of chemotherapy-induced peripheral neuropathy are limited.
23 no effective disease-modifying therapies for chemotherapy-induced peripheral neuropathies, but these
24                                              Chemotherapy induced peripheral neuropathy (CIPN), a tox
25 for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 in
26                                              Chemotherapy-induced peripheral neuropathy (CIPN) accomp
27                                              Chemotherapy-induced peripheral neuropathy (CIPN) affect
28 erapy may be correlated with the severity of chemotherapy-induced peripheral neuropathy (CIPN) after
29 e an understanding of the pathophysiology of chemotherapy-induced peripheral neuropathy (CIPN) and ma
30 enotype in a preclinical model of bortezomib chemotherapy-induced peripheral neuropathy (CIPN) and to
31                                              Chemotherapy-induced peripheral neuropathy (CIPN) arises
32                                              Chemotherapy-induced peripheral neuropathy (CIPN) impact
33  and reversed neuropathic pain in a model of chemotherapy-induced peripheral neuropathy (CIPN) in wil
34                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a c
35                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a c
36                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a c
37                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a c
38                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a d
39                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a d
40                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a d
41                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a d
42 tment of CIPN.SIGNIFICANCE STATEMENT Painful chemotherapy-induced peripheral neuropathy (CIPN) is a d
43                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a m
44                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a m
45                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a m
46                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a m
47 uced neuropathic pain.SIGNIFICANCE STATEMENT Chemotherapy-induced peripheral neuropathy (CIPN) is a m
48                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a m
49                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a p
50 hanisms are warranted.SIGNIFICANCE STATEMENT Chemotherapy-induced peripheral neuropathy (CIPN) is a p
51                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a s
52                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a s
53                                              Chemotherapy-induced peripheral neuropathy (CIPN) is a s
54                                              Chemotherapy-induced peripheral neuropathy (CIPN) is com
55                                              Chemotherapy-induced peripheral neuropathy (CIPN) is one
56                          The pathogenesis of chemotherapy-induced peripheral neuropathy (CIPN) is poo
57                                              Chemotherapy-induced peripheral neuropathy (CIPN) is the
58                                              Chemotherapy-induced peripheral neuropathy (CIPN) is the
59                                      Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may pe
60                                              Chemotherapy-induced peripheral neuropathy (CIPN) occurs
61                                              Chemotherapy-induced peripheral neuropathy (CIPN) remain
62                                Management of chemotherapy-induced peripheral neuropathy (CIPN) remain
63 ancer therapy have improved remission rates, chemotherapy-induced peripheral neuropathy (CIPN) remain
64 ed massage therapy for symptomatic relief of chemotherapy-induced peripheral neuropathy (CIPN) to det
65 n of patients with acute and chronic painful chemotherapy-induced peripheral neuropathy (CIPN), a ser
66 oth prevent and reverse pain associated with chemotherapy-induced peripheral neuropathy (CIPN), a sev
67                                           In chemotherapy-induced peripheral neuropathy (CIPN), agent
68 e (HRQoL) and alleviate symptoms of fatigue, chemotherapy-induced peripheral neuropathy (CIPN), and g
69                                              Chemotherapy-induced peripheral neuropathy (CIPN), chara
70                                              Chemotherapy-induced peripheral neuropathy (CIPN), one o
71 v1.7 are increased in a preclinical model of chemotherapy-induced peripheral neuropathy (CIPN), the m
72 er survivors suffer from intractable painful chemotherapy-induced peripheral neuropathy (CIPN), which
73 y drug paclitaxel (PTX) causes dose-limiting chemotherapy-induced peripheral neuropathy (CIPN), which
74 s the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN).
75 -analysis of research using animal models of chemotherapy-induced peripheral neuropathy (CIPN).
76 duction and expression of paclitaxel-related chemotherapy-induced peripheral neuropathy (CIPN).
77 be useful in the prevention and treatment of chemotherapy-induced peripheral neuropathy in humans.
78                                              Chemotherapy-induced peripheral neuropathy is a common,
79                                              Chemotherapy-induced peripheral neuropathy is a dose-lim
80 eting of mitochondria.SIGNIFICANCE STATEMENT Chemotherapy-induced peripheral neuropathy is a major, d
81                                              Chemotherapy-induced peripheral neuropathy is among the
82                              The emphasis in chemotherapy-induced peripheral neuropathy is on trying
83                               Platinum-based chemotherapy-induced peripheral neuropathy is one of the
84                                              Chemotherapy-induced peripheral neuropathy is one of the
85 r, axon loss in most neuropathies, including chemotherapy-induced peripheral neuropathy, is the resul
86 nstellation of neurologic disorders known as chemotherapy-induced peripheral neuropathy, mechanistic
87 fe Questionnaire Core 30 [EORTC QLQ-C30] and Chemotherapy-Induced Peripheral Neuropathy Module [CIPN2
88 tem disorders, particularly those related to chemotherapy-induced peripheral neuropathies or CNS dise
89                                              Chemotherapy-induced peripheral neuropathy persists afte
90 ssociated with CFA injection, skin incision, chemotherapy induced peripheral neuropathy, sickle cell
91                  Among patients with painful chemotherapy-induced peripheral neuropathy, the use of d
92 t the role of histone deacetylase (HDAC)6 in chemotherapy-induced peripheral neuropathy, through mech